Deerfield Management’s Vaxcyte PCVX Stock Holding History

Deerfield Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-225,000	Closed	-$7.31M	–	167
2025 Q2	$7.31M	Hold	225,000	–	–	0.13%	70
2025 Q1	$8.5M	Hold	225,000	–	–	0.17%	73
2024 Q4	$18.4M	Hold	225,000	–	–	0.35%	54
2024 Q3	$25.7M	Buy	+225,000	New	+$20.3M	0.38%	54
2023 Q2	–	Sell	-295,000	Closed	-$11.1M	–	109
2023 Q1	$11.1M	Sell	295,000 -405,000	-58%	-$17.2M	0.25%	70
2022 Q4	$33.6M	Buy	+700,000	New	+$27.5M	0.69%	44

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Deerfield Management's PCVX Position: Q3 2025 in Review

Deerfield Management sold out of Vaxcyte (PCVX) in Q3 2025, closing a stake of 225,000 shares — an estimated $7.31M sold.

Deerfield Management first reported a position in PCVX in Q4 2022 and held it in 6 quarters. The position peaked at $33.6M in Q4 2022. 285 funds tracked by Wall St. Rank hold PCVX as of Q3 2025.

Deerfield Management reported no remaining Vaxcyte position as of Q3 2025 after selling out during the quarter.
Deerfield Management sold 225,000 Vaxcyte shares in Q3 2025, an estimated $7.31M.
Deerfield Management first reported a position in Vaxcyte in Q4 2022 and held it in 6 quarters.
Deerfield Management's Vaxcyte position peaked at $33.6M in Q4 2022.
285 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2025.

Based on Deerfield Management's 13F filing for Q3 2025, filed 14 Nov 2025.